Berlin Institute for Advanced Study

Briya Raises $11.5M Series A, Accelerates U.S. Rollout of Blockchain-Secured Data Exchange Platform to Enhance Collaboration Between Hospitals and Life Sciences

Retrieved on: 
Tuesday, September 19, 2023
Berlin Institute for Advanced Study, Arm, University, Newsweek, Electrical engineering, Privacy, Research, Radiology, Confidentiality, BIH, Computer, Organization, Hospital, Collection, Tel Aviv Sourasky Medical Center, Neuroradiology, Drug discovery, Ecosystem, Digital, AI, Berlin, Health information management, Insight Partners, Electricity, Cryptocurrency, Medical device, Pharmaceutical industry

NEW YORK, Sept. 18, 2023 /PRNewswire/ -- Briya, an end-to-end healthcare data exchange platform, today announced completion of an $11.5 million Series A round of financing, bringing the company's total funding to $17 million. The round was led by Team8, includes existing investors Insight Partners, Amiti Ventures and Innocare Health Investments, and is joined by the George Kaiser Family Foundation.

Key Points: 
  • The company's scalable data exchange platform enables hospitals to capitalize on their patient data.
  • The Briya platform connects clinics and hospitals with academic and pharmaceutical research teams, addressing the primary challenges faced by organizations in the collection and exchange of healthcare data.
  • The highly secured data exchange empowers hospitals to effectively utilize their health data and safely share it, in compliance with all regulatory guidelines.
  • "We expect to see Briya adopted as a scalable data exchange solution in institutes, hospitals, and organizations across the U.S. in the near future."

Wyss Center Geneva Appoints Erwin Böttinger as new Chief Executive Officer

Retrieved on: 
Monday, April 3, 2023
Mental Health, Technology, Medical Devices, Neurology, Biometrics, Other Health, Biotechnology, Health, Oncology, Artificial Intelligence, Monochorionic twins, Wyss Foundation, Hasso Plattner Institute, Berlin Institute for Advanced Study, Broad Institute, University, Wyss Center for Bio and Neuroengineering, Icahn School of Medicine at Mount Sinai, Bio, Multimedia, Research, Genomics, Mount Sinai, Translation, University of Geneva, Campus Biotech, DSM-IV codes, Digital health, MD, RTÉ Executive Board, Artificial intelligence, Psychiatry, CHF, Stanley Center for Psychiatric Research at Broad Institute, Geneva University Hospitals, Management, Pharmaceutical industry

The Executive Board of the Wyss Center for Bio and Neuroengineering, a non-profit research center, is pleased to announce the appointment of Prof. Dr. med.

Key Points: 
  • The Executive Board of the Wyss Center for Bio and Neuroengineering, a non-profit research center, is pleased to announce the appointment of Prof. Dr. med.
  • Erwin Böttinger as its new Chief Executive Officer (CEO).
  • Erwin Böttinger, Chief Executive Officer of the Wyss Center for Bio and Neuroengineering.
  • Since its founding, the Wyss Center has developed strong systems to advance vital technologies to the clinic.

Nuvo Group Partners with Charité - Universitätsmedizin Berlin to Establish a Remote Fetal Surveillance Protocol for Europe and Study Predictive Analytics on Preeclampsia Patients

Retrieved on: 
Wednesday, January 5, 2022
Contraindication, Nursing, CB Insights, Review, Research, Bed, Patient, Biomedical Research, Physician, TEL, Digital, Dentistry, Berlin Institute for Advanced Study, Department of Obstetrics and Gynecology (Massachusetts General Hospital), Pre-eclampsia, Education, Hypertension, Department, Biomarker, FDA, Woman, Partnership, Student, Fast Company, BIH, Population, INVU, Technology, Israel Innovation Authority, Fetal viability, Multimedia, Industry, Medical school, Academic health science centre, Parent, Pharmaceutical industry, Medical imaging, Nuvo, Charitable activities related to the COVID-19 pandemic, Obstetrics

In addition, the trial aims to identify predictive pathways for preeclamptic patients by extracting raw data from the INVU platform.

Key Points: 
  • In addition, the trial aims to identify predictive pathways for preeclamptic patients by extracting raw data from the INVU platform.
  • Hypertension, the key indicator of preeclampsia, occurs in up to 10% of pregnancies.
  • By pioneering a method to identify biomarkers for preeclampsia in its earliest stages, this partnership has a unique potential to improve outcomes for even the most at-risk patients.
  • For more information and complete indications, contraindications, warnings and precautions along with instructions for use, visit: www.nuvocares.com .

U2 ACHTUNG BABY 30TH ANNIVERSARY EDITION

Retrieved on: 
Monday, November 15, 2021
Darkness, Grammy Award for Best Rock Performance by a Duo or Group with Vocal, Interscope Records, The Real Thing, Trabant, Hansa Tonstudio, Windmill Lane Studios, View, Record, Special edition, Berlin Institute for Advanced Study, Sirius XM, Island Records, Music, Bono, Phillips, Achtung Baby, Grammy Awards, Zoo TV Tour, Multimedia, Sound, Who's Gonna Ride Your Wild Horses, Man, Sale, Noir, The Joshua Tree, The New York Times, Berlin Wall, Los Angeles Times, Fly, Yucca brevifolia, Cassette tape, Nightclub

"[Achtung Baby] U2's daring descent into darkness" - Robert Hilburn, LA Times

Key Points: 
  • "[Achtung Baby] U2's daring descent into darkness" - Robert Hilburn, LA Times
    Thirty years ago, Bono described Achtung Baby as "the sound of four men chopping down The Joshua Tree" while Jon Pareles of the New York Times wrote that "stripped-down and defying its old formulas, U2 has given itself a fighting chance for the 1990's".
  • Recorded over six months at Hansa Studio in Berlin and Windmill Lane in Dublin, Achtung Baby is U2's seventh studio album.
  • Produced by long-time U2 collaborators Daniel Lanois and Brian Eno with Steve Lillywhite, Achtung Baby was engineered by Flood and released on November 18, 1991.
  • For more information, visit :
    Achtung Baby (30th Anniversary Edition) is available on Standard black vinyl and Deluxe color vinyl on November 19, with Achtung Baby (2018 Remaster) and Achtung Baby (Unter Remixes) also available digitally that day.

A new study using the SomaScan® Platform makes the connection between genes and proteins and their impact on human disease

Retrieved on: 
Wednesday, October 20, 2021
Berlin Institute for Advanced Study, Gene, NASDAQ, Risk, Twitter, SomaLogic, Protein, University, Disease, Research, Varicose veins, Joint, Nasdaq, RUO, Hypermobility, GLOBE, Carpal tunnel syndrome, Patient, Forward-looking statement, Blood, Plasma, Hernia, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dietary supplement, Vaccine, Risk management

Proteins in the body are encoded by our genes and any malfunction in the approximately 20,000 proteins in the human body can cause disease.

Key Points: 
  • Proteins in the body are encoded by our genes and any malfunction in the approximately 20,000 proteins in the human body can cause disease.
  • In fact, its estimated that most disease is caused by protein malfunction and because of this, proteins are the most common target of drug therapies to treat disease.
  • Until recently, the connection between genetic encoding of proteins and the impact of these proteins on diseases has been poorly understood because scientists were uncertain which genes are truly involved in these processes.
  • Among the key findings of the study was the identification of 10,674 genetic variant-protein associations, or pQTLs, for 3,892 distinct proteins.